PTN News

  • PTN Supports The ABC Science Collaborative October 7, 2020
    The Pediatric Trials Network (PTN), in partnership with others, supports the development of The ABC Science Collaborative. Funded by the National Institutes of Health, The Collaborative works to pair scientists and physicians with public school and community leaders to help understand the most current information about COVID-19. PTN Steering Committee Chair and Co-Lead of The ABC ...
  • PTN evaluates COVID-19 in younger patients August 17, 2020
    The Pediatric Trials Network (PTN), NICHD Funded, Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children per Standard of Care (POP02) Study continues to evolve in an effort to support the treatment of younger COVID-19 patients. POP02 is now evaluating several therapeutics to potentially treat COVID-19 patients age 0 – <21 years old. “With ...
  • PTN sildenafil study opens second cohort July 16, 2020
    The Pediatric Trials Network (PTN) opened the second cohort, or group of study participants, in the Safety of Sildenafil in Premature Infants study. This is a major study milestone, as it will determine the safety of 0.5 mg/kg of sildenafil in premature infants. The first cohort received a smaller dose of 0.125 mg/kg. The third, ...
  • LAPS trial achieves substantial enrollment milestone June 25, 2020
    The PTN Long-term Antipsychotic Pediatric Safety (LAPS) Trial has now passed the halfway mark of enrollment, marking a substantial study milestone. The two-year LAPS study will follow children aged 3 to 17 who are already taking an antipsychotic (risperidone or aripiprazole) to treat disorders such as schizophrenia, bipolar disorder, and irritability associated with autism. The study ...
  • Digoxin study achieves substantial milestone May 31, 2020
    The PTN digoxin study has achieved more than 20% of participant enrollment goals and has activated all sites. The study, which enrolled the first participant in the summer of 2019, will determine the pharmacokinetics (how a drug travels through the body) and safety of digoxin prescribed to infants with single ventricle congenital heart disease (CHD). While digoxin has been ...
  • POP02 begins study enrollment May 26, 2020
    The Pediatric Trials Network (PTN) has started enrolling participants in the Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children per Standard of Care (POP02) study. POP02 aims to expand upon the work done as part of PTN POPS, with hopes to shrink the gap between pediatric and adult dosing information available to prescribing ...
  • NIH funding opportunity for PTN consultative resources May 12, 2020
    The National Institutes of Health (NIH) has released a funding opportunity announcement (FOA) that will help investigators obtain access to consultative resources through the Pediatric Trials Network (PTN) and the Best Pharmaceuticals for Children Act (BPCA) Data Coordinating Center. The primary goal is to aid researchers in the planning phase of single or multi-site, investigator initiated ...
  • Database locked for Levetiracetum as part of AED study April 30, 2020
    The Pediatric Trials Network (PTN) has locked the database for Levetiracetam, one drug included in the Pharmacokinetics (PK) of Anti-epileptic Drugs in Obese Children (AED) study. “With this study, the PTN and its sites have addressed the important, but under recognized problem of how obesity impacts drug pharmacokinetics in children.   It can be hoped that the ...
  • PTN assists in learning more about potential COVID-19 treatment drugs April 28, 2020
    In record speed, the Pediatric Trials Network (PTN) worked to collaboratively and successfully stand up an extended component of the Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children per Standard of Care (POP02) to focus on six drugs that have the potential to be involved in the treatment of COVID-19. The completed ...
  • PTN’s Clindamycin research informs FDA label change March 30, 2020
    The U.S. Food and Drug Administration (FDA) has updated the prescribing information, or drug label, of Clindamycin, based on data provided by the Pediatric Trials Network (PTN). The updated label now includes dosing guidelines for children with obesity. “Sometimes in children with obesity, the way the body absorbs and processes drugs is different than in other ...
 
 

News icon

news